BioSpace News Archive

Immunocore Holdings plc (Nasdaq: IMCR), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, autoimmune and infectious diseases, today presented data for IMC-C103C, a bispecific T cell engager targeting MAGE-A4, in patients with ovarian cancer.

Be Biopharma (“Be Bio”) today announced the appointment of John Mayfield, Ph.D., to the newly created position of Chief Business Officer.

Asensus Surgical, Inc. today announced that a Senhance ® Surgical System has been sold to the Company’s distribution partner in Germany focused on Eastern Europe and the Commonwealth of Independent States (CIS) region.

Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced positive top-line data from the RAPIDe-1 Phase 2 clinical study, demonstrating statistically significant results of PHVS416 as an oral on-demand treatment for HAE attacks.

BD (Becton, Dickinson and Company) today announced the release of its second annual Global Inclusion, Diversity and Equity Report for fiscal year 2022.

IN8bio, Inc. today announced that it has received received clearance of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) to initiate a Phase 2 clinical trial of a genetically modified autologous gamma-delta T cell therapy (INB-400) targeting newly diagnosed glioblastoma (GBM).

XORTX Therapeutics Inc. is pleased to announce new proof of concept data demonstrating, in a second study, the effectiveness of xanthine oxidase inhibition (“XOI”) produced by the Company’s proprietary oral oxypurinol formulation, XORLO TM.

BIOXYTRAN, INC. announced the receipt of an Investigational New Drug (IND) authorization letter from India’s Central Drugs Standard Control Organization (CDSCO) to optimize dosage in Covid-19 patients.

Currently circulating mutant strains of influenza highlight the need for multi-target diagnostic tests.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced a global collaboration focused on discovering and developing intracellular Endosomal Escape Vehicle (EEV™) therapeutics for myotonic dystrophy type 1 (DM1).